Biominhai Collaborates with Dek Vaccines for 13-Valent PCV Technology Transfer and Drug Supply

We are thrilled to announce that Biominhai, a subsidiary of Kangtai Group, has signed a groundbreaking technology transfer and supply agreement with DEK Vaccines Limited for the production of the 13-valent Pneumococcal Vaccine (PCV-13) in Accra, Ghana.
This partnership aims to enhance vaccine sovereignty and health security in West and Central Africa by supplying PCV-13 to public and private markets, including key organizations like UNICEF, GAVI, and PAHO.
Together, we are committed to building local manufacturing capacity and ensuring access to essential vaccines for the African population. This initiative not only strengthens our production capabilities but also contributes to the global fight against infectious diseases.
Stay tuned for more updates as we embark on this meaningful journey!